(1) VERY SUBSTANTIAL ACQUISITION IN RELATION TO ACQUISITION OF TRANSFERRED PRODUCTS, IN-LICENSING OF LICENSED PRODUCTS AND PROPOSED ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE&#x3b; (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE PURCHASE ARRANGEMENTS, ROYALTY PAYMENTS AND MILESTONE PAYMENTS&#x3b; AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING

Documents on Display Multi-Files

NOTICE OF EXTRAORDINARY GENERAL MEETING

FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON WEDNESDAY, OCTOBER 16, 2024

CLOSURE OF REGISTER OF MEMBERS FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON OCTOBER 16, 2024

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-502 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-1001 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Next Day Disclosure Return

FURTHER DELAY IN DESPATCH OF CIRCULAR IN RELATION TO (1) VERY SUBSTANTIAL ACQUISITION IN RELATION TO ACQUISITION OF TRANSFERRED PRODUCTS, IN-LICENSING OF LICENSED PRODUCTS AND PROPOSED ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE AND (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE PURCHASE ARRANGEMENT, ROYALTY PAYMENTS AND MILESTONE PAYMENTS

2024 Interim Report

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2024

DELAY IN DESPATCH OF CIRCULAR IN RELATION TO (1) VERY SUBSTANTIAL ACQUISITION IN RELATION TO ACQUISITION OF TRANSFERRED PRODUCTS, IN-LICENSING OF LICENSED PRODUCTS AND PROPOSED ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE AND (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE PURCHASE ARRANGEMENT, ROYALTY PAYMENTS AND MILESTONE PAYMENTS

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return (Resubmission)

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET SHARE REPURCHASE

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

(1) VERY SUBSTANTIAL ACQUISITION IN RELATION TO ACQUISITION OF TRANSFERRED PRODUCTS, IN-LICENSING OF LICENSED PRODUCTS AND PROPOSED ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE AND (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE PURCHASE ARRANGEMENT, ROYALTY PAYMENTS AND MILESTONE PAYMENTS

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2024

NOTICE OF BOARD MEETING

VOLUNTARY ANNOUNCEMENT BIOLOGIC LICENSE APPLICATION FOR OT-702 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2024

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2024

(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2024

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2024

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 20, 2024

NOTICE OF ANNUAL GENERAL MEETING

PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITOR; PROPOSED AMENDMENTS TO THE 2021 SHARE OPTION SCHEME; PROPOSED AMENDMENTS TO THE 2021 SHARE AWARD SCHEME; AND NOTICE OF ANNUAL GENERAL MEETING

Documents on Display Multi-Files

PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES&#x3b; PROPOSED RE-ELECTION OF RETIRING DIRECTORS&#x3b; PROPOSED RE-APPOINTMENT OF AUDITOR&#x3b; PROPOSED AMENDMENTS TO THE 2021 SHARE OPTION SCHEME&#x3b; PROPOSED AMENDMENTS TO THE 2021 SHARE AWARD SCHEME&#x3b; AND NOTICE OF ANNUAL GENERAL MEETING

Next Day Disclosure Return

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2024

2023 Annual Report

2023 Environmental, Social and Governance Report

VOLUNTARY ANNOUNCEMENT PRIMARY ENDPOINTS ACHIEVED IN THE PHASE III CLINICAL TRIAL OF OT-502 IN CHINA

VOLUNTARY ANNOUNCEMENT COMPLETION OF THE PHASE III CLINICAL TRIAL OF OT-702 IN CHINA

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024

(I) PROPOSED AMENDMENTS TO THE 2021 SHARE OPTION SCHEME; AND (II) PROPOSED AMENDMENTS TO THE 2021 SHARE AWARD SCHEME

(I) PROPOSED AMENDMENTS TO THE 2021 SHARE OPTION SCHEME&#x3b; AND (II) PROPOSED AMENDMENTS TO THE 2021 SHARE AWARD SCHEME

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

VOLUNTARY ANNOUNCEMENT PRIMARY ENDPOINTS ACHIEVED IN THE PHASE II CLINICAL TRIAL OF OT-202

DATE OF BOARD MEETING

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024

Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2024

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

DISCLOSEABLE TRANSACTION DISPOSAL OF SHARES IN EYEPOINT PHARMACEUTICALS, INC.

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return (Resubmission)

Next Day Disclosure Return (Resubmission)

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2023

Next Day Disclosure Return

Next Day Disclosure Return